← Back to Search

Virtual Reality Condition for Virtual Reality

N/A
Waitlist Available
Led By Erick Kim, M.S.
Research Sponsored by Palo Alto University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Any individuals who are a general adult population (18-64), be able to read English, and United States Residents. Individuals must be able to read English as all surveys are provided in English.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 5 minutes after start of the study
Awards & highlights

Study Summary

Depression has a lifetime prevalence rate of 20.6% and has one of the highest prevalence rates of mental health disorders. Major depressive disorder can lead to higher costs of living for individuals as well as a larger economic decrease associated with inability to work. Current treatment targets one of the two core symptoms of depression of decreased mood or loss of interest in activities. However, current treatment models are not enough because there are more individuals who require treatment than treatment opportunities which creates inequities of care. Digital interventions provide a unique opportunity to increase widespread accessibility of treatment at reduced and scalable costs. Virtual reality is a newer type of digital intervention that consists of providing experiences for individuals that are different from the physical environment they are currently in. Through audio and visual displays, virtual reality creates a sense of presence, or the experience of immersion, with an environment. Virtual reality has been used in a variety of clinical psychology areas such as training, assessment, and treatment of mental health disorders and other medical conditions. Despite research finding efficacy for virtual reality with anxiety and PTSD, few studies have examined the impact of virtual reality on depressive disorders and low mood. Of studies that have looked at mood changes, most studies measured indirect measures of mood such as energy levels which leads to a gap of research on the efficacy of virtual reality with low mood. The present study aims to examine if virtual reality exergames improve participant's mood and affect. Additionally, the study will determine if there are different effects of presence, depressive symptoms, and technology familiarity on mood. Furthermore, the study will examine helpfulness and satisfaction to examine usability of virtual reality as a medium for clinical intervention. Lastly, findings of this study could inform the development and efficacy of virtual reality interventions that can be used to provide more access to treatment for individuals and improve outcomes to reduce the burdens associated with depression.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 5 minutes after start of the study
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 5 minutes after start of the study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Positive and Negative Affect Schedule
Secondary outcome measures
Affinity for Technology Interaction Scale (ATI)
Patient Health Questionnaire depression scale (PHQ-8)
Temple Presence Inventory
Other outcome measures
Change in Mood Rating Scale
Media Feedback Questions
Net Promoter Score

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Virtual Reality ConditionExperimental Treatment1 Intervention
Participants will be using a virtual reality headset to engage with a mountain climbing game.
Group II: Control ConditionActive Control1 Intervention
Participants will be mimicking hand movements displayed on a television screen.

Find a Location

Who is running the clinical trial?

Palo Alto UniversityLead Sponsor
12 Previous Clinical Trials
7,835 Total Patients Enrolled
Erick Kim, M.S.Principal InvestigatorPalo Alto University
Eduardo Bunge, Ph.D.Principal InvestigatorPalo Alto University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~19 spots leftby Apr 2025